Association of Chronic Hepatitis C Infection Related Depression, Anxiety, and Neurocognitive Performance Achieving SVR-12 with Direct-Acting Antivirals: A Prospective Cohort Study

2021 ◽  
Author(s):  
Harmanpreet Kaur ◽  
Radha K. Dhiman ◽  
Anand V. Kulkarni ◽  
Madhumita Premkumar ◽  
Virendra Singh ◽  
...  
BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e026703 ◽  
Author(s):  
Chung-Feng Huang ◽  
Ming-Lun Yeh ◽  
Ching-I Huang ◽  
Po-Cheng Liang ◽  
Yi-Hung Lin ◽  
...  

ObjectiveThe treatment outcome of direct-acting antivirals (DAAs) in chronic hepatitis C patients with hepatocellular carcinoma (HCC) is controversial. The current study aimed to address the treatment efficacy and safety of DAAs in patients with curative or active HCC, compared with those of patients without HCC.DesignA prospective cohort studySettingA medical centre and two regional hospitals in TaiwanParticipantsA total of 713 Taiwanese patients (601 non-HCC, 74 curative HCC and 38 active HCC patients) who received standard-of-care DAAs were consecutively enrolled in the study.Main outcome measurementThe primary objective was to determine treatment efficacy, defined as undetectable hepatitis C virus RNA throughout 12 weeks of the post-treatment follow-up period (sustained virological response 12 [SVR12]).ResultsThe overall SVR12 rate was 96.9%. The SVR12 rate was similar between the patients with HCC and those without HCC (95.5% vs 97.2%, p=0.37). The HCC patients were divided into two groups, those with curative HCC and those with viable HCC; a substantially but not significantly lower SVR rate, 92.1% (35/38), was observed in the patients with viable HCC compared with the SVR rate, 97.3% (72/74), in those with curative HCC (p=0.33). Compared with the patients with curative HCC, the patients with viable HCC had a significantly higher proportion of serious adverse events (10.5% vs 1.0%, p=0.002), early treatment discontinuation (10.5% vs 2.8%, p=0.03) and mortality (5.3% vs 0.1%, p=0.008).ConclusionsAn equivalently high SVR rate was observed in patients with either past or active HCC compared with those without HCC. The safety concerns in the HCC patients did not compromise treatment efficacy.


The Lancet ◽  
2019 ◽  
Vol 393 (10179) ◽  
pp. 1453-1464 ◽  
Author(s):  
Fabrice Carrat ◽  
Hélène Fontaine ◽  
Céline Dorival ◽  
Mélanie Simony ◽  
Alpha Diallo ◽  
...  

2012 ◽  
Vol 8 (1) ◽  
pp. e1002339 ◽  
Author(s):  
Bambang S. Adiwijaya ◽  
Tara L. Kieffer ◽  
Joshua Henshaw ◽  
Karen Eisenhauer ◽  
Holly Kimko ◽  
...  

2018 ◽  
Vol 7 (3) ◽  
pp. 373-385 ◽  
Author(s):  
Patricia A. M. Kracht ◽  
Faydra I. Lieveld ◽  
Linde M. Amelung ◽  
Carina J. R. Verstraete ◽  
Eveline P. Mauser-Bunschoten ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document